Insulet Corp Stock Price, News & Analysis

Insulet Corporation (NASDAQ: PODD) reported strong third-quarter results for the period ending September 30, 2021, with revenues of $275.6 million, reflecting a 17.8% year-over-year increase. Notably, Omnipod revenue surged to $260.3 million, a growth of 22.7%. Operating income reached $33.7 million with a gross margin of 68.5%. Despite a 30.1% decline in Drug Delivery revenue, net income rose to $12.6 million. The company also updated its revenue guidance for the year to 18%-20% growth and confirmed a low double-digit operating margin expectation.

Insulet Corporation (NASDAQ: PODD) has appointed Luciana Borio, M.D., to its Board of Directors, bringing extensive government and public health experience. Dr. Borio has held significant roles at the FDA and National Security Council, specializing in medical product development and biodefense. Her expertise is expected to enhance Insulet's growth strategy. Additionally, Sally W. Crawford will retire from the Board effective December 31, 2021, after 13 years of service, with gratitude expressed for her contributions.

Insulet Corporation (NASDAQ: PODD) reported positive results from its pivotal trial extension for the Omnipod 5 Automated Insulin Delivery System, demonstrating significant improvements in diabetes management for users aged 6-70. Over 12 months, participants showed sustained reductions in HbA1c, with adults decreasing from 7.2% to 6.8% and children from 7.7% to 7.0%. Additionally, time in range increased notably. Insulet also presented data on the Omnipod DASH, highlighting a decrease in hypoglycemic events. The Omnipod 5 is expected to launch in the US in late Q4 2021.

Insulet Corporation (NASDAQ: PODD) announced its plan to release third quarter financial results on November 4, 2021, after market close. Management will hold a conference call at 4:30 p.m. ET to discuss the results. Insulet is known for its innovative Omnipod insulin management system, which offers a needle-free, wearable insulin delivery option. The company aims to simplify life for people with diabetes through its unique product platform. Investors can access the call via the company's Investor Relations website.

Insulet Corporation (NASDAQ: PODD) will present at three virtual investor conferences: the Wells Fargo Healthcare Conference on September 9, the Morgan Stanley Global Healthcare Conference on September 10, and the Baird Global Healthcare Conference on September 15, 2021. Each presentation will be accessible via live webcasts, which will also have replays available afterwards. Insulet specializes in innovative diabetes management technology, specifically its Omnipod tubeless insulin delivery system, designed to simplify life for individuals with diabetes.

Insulet Corporation (NASDAQ: PODD) has received FDA clearance to use Eli Lilly's Lyumjev® (insulin lispro-aabc) with its Omnipod® Insulin Management System. Insulet is the only U.S. insulin pump manufacturer authorized for this use, enhancing flexibility for diabetes management. Lyumjev, a rapid-acting insulin, improves post-meal glucose control and is effective when delivered via continuous subcutaneous insulin infusion. This collaboration with Lilly aims to simplify diabetes care by providing more options for insulin administration.

Insulet Corporation (NASDAQ: PODD) announced the upcoming launch of the Omnipod DASH Insulin Management System in Australia at the Australasian Diabetes Congress. Orders are expected to be taken by the end of August. The Omnipod DASH is the first waterproof, tubeless insulin pump in Australia, designed to provide insulin therapy for up to 72 hours. This launch is part of Insulet’s global expansion strategy, which previously included markets in Europe and the Middle East. The new system aims to simplify diabetes management with its intuitive design and customer-centric business model.

Insulet Corporation (NASDAQ: PODD) reported Q2 2021 revenues of $263.2 million, a 16.3% increase from the prior year. Omnipod revenue reached $242.1 million with a 19.9% increase. U.S. Omnipod revenue was $150.5 million (up 16.8%), while international revenue hit $91.6 million (up 25.1%). Despite a gross margin rise to 69.4%, the company reported a net loss of $25.0 million due to a debt extinguishment loss. Adjusted EBITDA improved to $52.3 million. Insulet reaffirms its 2021 revenue guidance of 16%-20% growth.